Medications received by patients with juvenile dermatomyositis.

ABSTRACT:

Objective

Few controlled studies are available to guide treatment decisions in juvenile dermatomyositis (JDM). This study evaluated therapies received, changes of treatment over time, and factors associated with medication choices in JDM.

Methods

We performed a retrospective analysis of the number and type of therapies and duration of treatment for 320 patients with JDM enrolled in a North American registry. Kaplan-Meier and logistic regression analysis were used to assess the association of demographic and clinical features and autoantibodies with medication usage.

Results

High-dose oral prednisone was the primary therapy given to 99% of patients. 1997 was determined to be a threshold year for increasing usage of medications other than prednisone. The median time to

SUBMITTER: Kishi T 

PROVIDER: S-EPMC6162169 | biostudies-literature | 2018 Dec

REPOSITORIES: biostudies-literature